Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Monday, Hepion Pharmaceuticals Inc (NASDAQ: HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination product candidate in development for Parkinson's Disease.
周一，hepion pharmaceuticals通过与晚期临床阶段的以色列私人公司Pharma Two b Ltd.达成了明确的合并协议，该公司正在开发一种针对帕金森病的组合产品候选药物P2B001。
The merger is valued at an estimated pro-forma implied equity value of approximately $58.5 million.
本并购估值约为5850万美元的拟议股权价值。
Hepion will merge into and become an indirectly wholly-owned subsidiary of Pharma Two B.
Hepion将合并并成为Pharma Two b的间接全资子公司。
The combined company will continue to operate under the "Pharma Two B" name. Pharma Two B has agreed to file a registration statement with the SEC to register the ordinary shares proposed to be issued to Hepion's equity holders in the acquisition. It will also apply to list its ordinary shares on Nasdaq under the ticker symbol "PHTB."
合并后的公司将继续使用“Pharma Two B”名称。Pharma Two b已同意向SEC提交注册声明，以注册拟出售给Hepion股权持有人的普通股。其还将申请将其普通股在纳斯达克以“PHTb”股票代码上市。
"P2B001 offers a novel, easy-to-use therapeutic approach, that is designed to address the unmet need for an effective, safe, once-daily, no titration required treatment with a lower incidence of excessive daytime sleepiness—a common side effect of currently available dopamine agonist treatments in Parkinson's disease patients" said Dan Teleman, Chief Executive Officer of Pharma Two B.
Pharma Two b的首席执行官Dan Teleman表示：“P2B001提供了一种新颖、易于使用的治疗方法，旨在满足帕金森病患者治疗需求的未满足之处。该疗法无需逐渐增加剂量，一天只需服用一次，并且副作用低——目前可用的多巴胺激动剂治疗常见副作用为过度昼间嗜睡。”
"Our company is in a stage that we believe meets the public market and investors' expectations. We are excited about Pharma Two B's next growth phase, moving P2B001 towards an NDA submission targeted for the first half of 2026 and making this potential treatment available to patients," he continued.
"我们公司处于一个我们认为满足公众市场和投资者期望的阶段。我们对Pharma Two B的下一个成长阶段感到兴奋，将P2B001推向预计在2026年上半年提交NDA，并使这种潜在的治疗方法可供患者使用，"他继续说道。
Hepion has also announced a private placement of $2.9 million non-convertible senior notes to qualified institutional investors.
Hepion还宣布向符合资格的机构投资者进行了290万美元的不可转换优先债券的定向增发。
Pharma Two B has entered into a securities purchase agreement for an $11.5 million private placement of ordinary shares and accompanying Series A warrants and Series B warrants.
Pharma Two b已与证券购买协议签署，进行了1150万美元的普通股和附带的A类认股权证和B类认股权证的定向增发。
In April, Hepion Pharmaceuticals began wind-down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as previously announced in December 2023.
2023年12月前已宣布的公告中，Hepion Pharmaceuticals在ASCEND-NASH试验中开始了缩减活动，同时继续探索战略性选择。
Price Action: HEPA stock is up 1.96% at $1.04 during the premarket session at last check Monday.
股票代码为HEPA的股票周一盘前交易中涨幅为1.96%，报价为1.04美元。